Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

Journal of Clinical Oncology

Volumn 13, Issue 10, 1995, Pages 2575-2581

  Seidman, A D ^a   Tiersten, A ^b   Hudis, C ^b   Gollub, M ^b   Barrett, S ^b   Yao, T J ^b   Lepore, J ^b   Gilewski, T ^b   Currie, V ^b   Crown, J ^b   Hakes, T ^b   Baselga, J ^b   Sklarin, N ^b   Moynihan, M E ^b   Tong, W ^b   Egorin, M ^b   Kearns, C ^b   Spriggs, D ^b   Norton, L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029148461     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.10.2575     Document Type: Article

References (28)

1. Manfredi JJ, Horwitz SB: Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther 25:83-125, 1984
2. McGuire WP, Rowinsky EK, Rosenstein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
3. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
4. Reichman BS, Seidman AD, Crown J, et al: Paclitaxel and recombinant human granulocyte stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
5. Murphy W, Fossella F, Winn R, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
6. Rowinsky EK, McGuire WP, Guanieri T, et al: Cardiac disturbances during the administration of Taxol. J Clin Oncol 9:1704-1712, 1991
7. Kris M, O'Connell J, Gralla R, et al: Phase I trial of Taxol given as a 3 hour infusion every 21 days. Cancer Treat Rep 70:605-607, 1986
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton K, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
9. Gelmon K, Nabholtz JM, Bontebal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer after failure of standard therapy. Ann Oncol 5:198, 1994 (suppl 5) (abstr 493)
10. Adler L, Herzog T, Williams S, et al: Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer 74:1891-1898, 1994
11. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993 (abstr)
12. Abrams JS, Vena DA, Baitz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
13. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
14. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987
15. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
16. 2. J Clin Oncol 12:1741-1742, 1994 (letter)
17. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
18. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
19. Vermorken JB, Huizing MT, Liefting AJM, et al: High-dose Taxol with G-CSF in patients with advanced breast cancer refractory to anthracycline therapy. Proceedings of the Seventh European Congress on Clinical Oncology, Jerusalem, Israel, November 1993 (abstr 435)
20. Capri G, Munzone E, Tarenzi E, et al: Optic nerve disturbances: A new form of puclitaxel neurotoxicity. J Natl Cancer Inst 86:1099-1101, 1994
21. Seidman AD: The emerging role of paclilaxcl in breast cancer therapy. Clin Cancer Res 1:247-256, 1995
22. Seidman AD, Reichman B, Crown J, et al: Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for melastatic breast cancer: A preliminary report. Monogr Natl Cancer Inst 15:171-175, 1993
23. Hainsworth J, Greco A: Paclitaxel administered by 1-hour infusion-preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377-1382, 1994
24. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
25. Wilson W, Berg S, Bryant G, et al: Paclitaxel in doxorubicinrefractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
26. Seidman AD, Hochhauser D, Yao T-J, et al: 96 hour paclitaxel after prior short taxane infusion: Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Proc Am Soc Clin Oncol 14:113, 1995 (abstr 151)
27. Zhan Z, Kang YK, Regis J, et al: Taxol resistance: In vitro and in vivo studies in breast cancer and lymphoma. Proc Am Assoc Cancer Res 34:215, 1993 (abstr)
28. Seidman AD, Portenoy R, Yao T-J, et al: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87:1316-1322, 1995